Top

Published in:

Open Access 01-07-2017

T₁ mapping in cardiac MRI

Authors: Dina Radenkovic, Sebastian Weingärtner, Lewis Ricketts, James C. Moon, Gabriella Captur

Published in: Heart Failure Reviews | Issue 4/2017

Abstract

Quantitative myocardial and blood T₁ have recently achieved clinical utility in numerous pathologies, as they provide non-invasive tissue characterization with the potential to replace invasive biopsy. Native T₁ time (no contrast agent), changes with myocardial extracellular water (edema, focal or diffuse fibrosis), fat, iron, and amyloid protein content. After contrast, the extracellular volume fraction (ECV) estimates the size of the extracellular space and identifies interstitial disease. Spatially resolved quantification of these biomarkers (so-called T₁ mapping and ECV mapping) are steadily becoming diagnostic and prognostically useful tests for several heart muscle diseases, influencing clinical decision-making with a pending second consensus statement due mid-2017. This review outlines the physics involved in estimating T₁ times and summarizes the disease-specific clinical and research impacts of T₁ and ECV to date. We conclude by highlighting some of the remaining challenges such as their community-wide delivery, quality control, and standardization for clinical practice.

Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392–398PubMedCrossRef

Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18:89–101PubMedPubMedCentralCrossRef

Higgins DM, Moon JC (2014) Review of T1 mapping methods: comparative effectiveness including reproducibility issues. Curr Cardiovasc Imaging Rep 7:9252CrossRef

Fent GJ, Garg P, Foley JRJ, Swoboda PP, Dobson LE, Erhayiem B, Greenwood JP, Plein S, Treibel TA, Moon JC (2017) Synthetic myocardial extracellular volume fraction. JACC Cardiovasc Imaging. doi:10.1016/jcmg.2016.12.007

Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J, Nasis A, Bhuva AN, Bulluck H, Abdel-Gadir A, White SK, Manisty C, Spottiswoode BS, Wong TC, Piechnik SK, Kellman P, Robson MD, Schelbert EB, Moon JC (2016) Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. JACC Cardiovasc Imaging 9:54–63PubMedCrossRef

Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP (2004) Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 52:141–146PubMedCrossRef

Kellman P, Wilson JR, Xue H, Ugander M, Arai AE (2012) Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson 14:63–74PubMedPubMedCentralCrossRef

Piechnik SK, Ferreira VM, Dall’Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD (2010) Shortened modified look-locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 12:69–80PubMedPubMedCentralCrossRef

Shao J, Rapacchi S, Nguyen K-L, Hu P (2016) Myocardial T1 mapping at 3.0 tesla using an inversion recovery spoiled gradient echo readout and bloch equation simulation with slice profile correction (BLESSPC) T1 estimation algorithm. J Magn Reson Imaging 43:414–425PubMedCrossRef

10.

Gensler D, Morchel P, Fidler F, Ritter O, Quick HH, Ladd ME, Bauer WR, Ertl G, Jakob PM, Nordbeck P (2015) Myocardial T1: quantification by using an ECG-triggered radial single-shot inversion-recovery MR imaging sequence. Radiology 274:879–887PubMedCrossRef

11.

Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB (2014) Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med 71:2082–2095PubMedCrossRef

12.

Slavin GS, Stainsby JA (2013) True T1 mapping with SMART1Map (saturation method using adaptive recovery times for cardiac T1 mapping): a comparison with MOLLI. J Cardiovasc Mag Res 15:P3. doi:10.1186/1532-429X-15-S1-P3 CrossRef

13.

Skulborstad EP, Borden ZS, Vigen KK, Slavin GS, Wang K, Schiebler ML, Nagle SK, Reeder SB, Grist TM, Francois CJ (2015) Myocardial T 1 Mapping Comparing SMART 1 Map and MOLLI: Clinical Experience at 3T. Abstract #2622 from ISMRM 23rd Annual Meeting

14.

Weingärtner S, Akçakaya M, Basha T, Kissinger KV, Goddu B, Berg S, Manning WJ, Nezafat R (2013) Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med 71(3):1024–1103CrossRef

15.

Weingärtner S, Roujol S, Akçakaya M, Basha TA, Nezafat R (2015) Free-breathing multislice native myocardial T1 mapping using the slice-interleaved T1 (STONE) sequence. Magn Reson Med 74:115–124CrossRef

16.

Mehta BB, Chen X, Bilchick KC, Salerno M, Epstein FH (2015) Accelerated and navigator-gated look-locker imaging for cardiac t1 estimation (ANGIE): development and application to T1 mapping of the right ventricle. Magn Reson Med 73:150–160PubMedCrossRef

17.

Everett RJ, Stirrat CG, Semple SIR, Newby DE, Dweck MR, Mirsadraee S (2016) Assessment of myocardial fibrosis with T1 mapping MRI. Clin Radiol 71:768–778PubMedCrossRef

18.

Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB (2013) Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15:92–104PubMedPubMedCentralCrossRef

19.

Roujol SS, Foppa M, Weingartner S, Manning WJ, Nezafat R, Weingärtner S, Manning WJ, Nezafat R (2014) Adaptive registration of varying contrast-weighted images for improved tissue characterization (ARCTIC): application to T1 mapping. Magn Reson Med 73(4):1469–1482PubMedPubMedCentralCrossRef

20.

Xue H, Shah S, Greiser A, Guetter C, Littmann A, Jolly MP, Arai AE, Zuehlsdorff S, Guehring J, Kellman P (2012) Motion correction for myocardial T1 mapping using image registration with synthetic image estimation. Magn Reson Med 67:1644–1655PubMedCrossRef

21.

Kellman P, Herzka DA, Arai AE, Hansen MS (2013) Influence of off-resonance in myocardial T1-mapping using SSFP based MOLLI method. J Cardiovasc Magn Reson 15:63PubMedPubMedCentralCrossRef

22.

Look DC, Locker DR (1970) Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 41:250–251CrossRef

23.

Deichmann R, Haase A (1992) Quantification of T1 values by SNAPSHOT-FLASH NMR imaging. J Magn Reson 96:608–612

24.

Kaptein R, Dijkstra K, Tarr C (1976) A single-scan Fourier transform method for measuring spin-lattice relaxation times. J Magn Reson 24:295–300

25.

Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M (2016) T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging 9:67–81PubMedCrossRef

26.

Higgins DM, Ridgway JP, Radjenovic A, Sivananthan UM, Smith MA (2005) T1 measurement using a short acquisition period for quantitative cardiac applications. Med Phys 32:1738–1746CrossRef

27.

Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, Lachmann RH, Murphy E, Mehta A, Hughes DA, McKenna WJ, Taylor AM, Hausenloy DJ, Hawkins PN, Elliott PM, Moon JC (2012) Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98:1436–1441PubMedCrossRef

28.

Chin CWL, Semple S, Malley T, White AC, Mirsadraee S, Weale PJ, Prasad S, Newby DE, Dweck MR (2014) Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 15:556–565PubMedCrossRef

29.

Treibel TA, Fontana M, Reant P, Espinosa MA, Castelletti S, Herrey AS, Manisty C, Roberts N, Yap J, Moon J (2015) T1 mapping in severe aortic stenosis: insights into LV remodeling. J Cardiovasc Magn Reson 17:O89PubMedCentralCrossRef

30.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechaleka ADR, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. J Am Coll Cardiol Img 7:157–165CrossRef

31.

aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnidzer D, Seitz S, Keller M, Schnabel PA, Giannitsis E, Korosoglou G, Katus H, Steen H (2015) T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging 16:210–216PubMedCrossRef

32.

Bulluck H, Rosmini S, Abdel-Gadir A, White SK, Bhuva AN, Treibel TA, Fontana M, Gonzalez-Lopez E, Reant P, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Kellman P, Moon JC, Hausenloy DJ (2016) Automated extracellular volume fraction mapping provides insights into the pathophysiology of left ventricular remodeling post-reperfused ST-elevation myocardial infarction. J Am Heart Assoc 5:7. doi:10.1161/JAHA.116.003555

33.

Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, Captur G, Anderson S, Piechnik SK, Robson MD, Lachmann RH, Murphy E, Mehta E, Hughes D, Kellman P, Elliott PM, Herrey AS, Moon JC (2014) Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 16:99. doi:10.1186/s12968-014-0099-4 PubMedPubMedCentralCrossRef

34.

Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, Robson MD, Neubauer S, Ariti C, Arai A, Kellman P, Yamamura J, Schoennagel BP, Shah F, Davis B, Trompeter S, Walker M, Porter J, Moon JC (2015) Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging 41:1505–1511. doi:10.1002/jmri.24727 PubMedCrossRef

35.

Hinojar R, Foote L, Arroyo Ucar E, Jackson T, Jabbour A, Yu CY, McCrohon J, Higgins DM, Carr-White G, Mayr M, Nagel E, Puntmann VO (2015) Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. J Am Coll Cardiol Img 8:37–46. doi:10.1016/j.jcmg.2014.07.016 CrossRef

36.

Kidambi A, Motwani M, Uddin A, Ripley DP, McDiarmid AK, Swoboda PP, Broadbent DA, Musa TA, Erhayiem B, Leader J, Croisille P, Clarysse P, Greenwood JP, Plein S (2016) Myocardial extracellular volume estimation by CMR predicts functional recovery following acute MI. J Am Coll Cardiol Img. doi:10.1016/j.jcmg.2016.06.015

37.

Singh A, Horsfield MA, Bekele S, Khan JN, Greiser A, McCann GP (2015) Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging 16:763–770. doi:10.1093/ehjci/jev007 PubMedCrossRef

38.

Swoboda PP, McDiarmid AK, Erhayiem B, Law GR, Garg P, Broadbent DA, Ripley DP, Musa TA, Dobson LE, Foley JR, Fent GJ, Page SP, Greenwood JP, Plein S (2017) Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypert rophic cardiomyopathy. J Cardiovasc Magn Reson 19(1):16. doi:10.1186/s12968-017-0334-x

39.

Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY (2014) CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 7(10):991–7

40.

McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent DA, Dobson LE, Musa TA, Ripley DP, Garg P, Greenwood JP, Ferguson C, Plein S (2016) Athletic cardiac adaptation in males is a consequence of elevated myocyte mass. Circ Cardiovasc Imaging 9:e003579. doi:10.1161/CIRCIMAGING.115.003579 PubMedPubMedCentral

41.

Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY (2013) T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6:637–645. doi:10.1161/CIRCIMAGING.113.000482 PubMedCrossRef

42.

Hanneman K, Nguyen ET, Thavendiranathan P, Ward R, Greiser A, Jolly MP, Butany J, Yang IY, Sussman MS, Wintersperger BJ (2016) Quantification of myocardial extracellular volume fraction with cardiac MR imaging in thalassemia major. Radiology 279:720–730. doi:10.1148/radiol.2015150341 PubMedCrossRef

43.

Fontana M, Chung R, Hawkins PN, Moon JC (2015) Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 20:133–144. doi:10.1007/s10741-014-9470-7 PubMedCrossRef

44.

Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gilmore JD, Hawkins PN, Moon JC (2015) Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277:388–397. doi:10.1148/radiol.2015141744 PubMedCrossRef

45.

Bohnen S, Radunski UK, Lund GK, Ojeda F, Looft Y, Senel M, Radziwolek L, Avanesov M, Tahir E, Stehning C, Schnackenburg B, Adam G, Blankenberg S, Muellerleile K (2017) Tissue characterization by T1 and T2 mapping cardiovascular magnetic resonance imaging to monitor myocardial inflammation in healing myocarditis. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jex007

46.

Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC (2013) Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6:34–39PubMedCrossRef

47.

Lurz JA, Luecke C, Lang D, Besler C, Rommel KP, Klingel K, Kandolf R, Adams V, Schöne K, Hindricks G, Schuler G, Linke A, Thiele H, Gutberlet M, Lurz P (2017) CMR-derived extracellular volume fraction as a marker for myocardial fibrosis: the importance of coexisting myocardial inflammation. JACC Cardiovasc Imaging. doi:10.1016/j.jcmg.2017.01.025

48.

Urbieta-Caceres VH, Zhu X-Y, Gibson ME, Favreau FD, Jordan K, Lerman A, Lerman LO (2011) Reversal of experimental renovascular hypertension restores coronary microvascular function and architecture. Am J Hypertens 24:458–465PubMedPubMedCentralCrossRef

49.

Putko BN, Wen K, Thompson RB, Mullen J, Shanks M, Yogasundaram H, Sergi C, Oudit GY (2015) Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 20:179–191. doi:10.1007/s10741-014-9452-9 PubMedCrossRef

50.

Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, Moon JC, Figtree GA (2016) Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart 102:298–302. doi:10.1136/heartjnl-2015-308494 PubMedCrossRef

51.

Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta E, Hughes D, Neubauer S, Elliott PM, Moon JC (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392–398. doi:10.1161/CIRCIMAGING.112.000070 PubMedCrossRef

52.

Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, Baig S, Mehta A, Hughes D, Moon JC (2016) Cardiac fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 68:1707–1708. doi:10.1016/j.jacc.2016.07.741 PubMedCrossRef

53.

Moon JCC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–2155PubMedCrossRef

54.

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P (2009) Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. JAC 53:1475–1487. doi:10.1016/j.jacc.2009.02.007

55.

Francone M, Chimenti C, Galea N, Scopelliti F, Verardo R, Galea R, Carbone I, Catalano C, Fedale F, Frustaci A (2014) CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. J Am Coll Cardiol Img 7:254–263. doi:10.1016/j.jcmg.2013.10.011 CrossRef

56.

Nadjiri J, Nieberler H, Hendrich E, Greiser A, Will A, Martinoff S, Hadamitzky M (2017) Performance of native and contrast-enhanced T1 mapping to detect myocardial damage in patients with suspected myocarditis: a head-to-head comparison of different cardiovascular magnetic resonance techniques. Int J Cardiovasc Imaging 33:539–547. doi:10.1007/s10554-016-1029-3 PubMedCrossRef

57.

Luetkens JA, Homsi R, Sprinkart AM, Doerner J, Dabir D, Kuetting DL, Block W, Andrie R, Stehning C, Fimmers R, Gieseke J, Thomas DK, Schild HH, Naehle CP (2016) Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis. Eur Heart J Cardiovasc Imaging 17:154–161. doi:10.1093/ehjci/jev246 PubMedCrossRef

58.

Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M (2016) Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. JAC 67:1800–1811. doi:10.1016/j.jacc.2016.02.013

59.

Lagan J, Schmitt M, Miller CA (2017) Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. Int J Cardiovasc Imaging. doi:10.1007/s10554-017-1063-9

60.

Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Mahrous A, Ford I, Tzemos N, Sattar N, Welsh P, Radjenovic A, Oldroyd KG, Berry C (2016) Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. Eur Heart J 37:1044–1059. doi:10.1093/eurheartj/ehv372 PubMedCrossRef

61.

Nakamori S, Alakbarli J, Bellm S, Motiwala SR, Addae G, Manning WJ, Nezafat R (2017) Native T1 value in the remote myocardium is independently associated with left ventricular dysfunction in patients with prior myocardial infarction. J Magn Reson Imaging. doi:10.1002/jmri.25652

62.

Chen YY, Ren DY, Zeng MS, Yang S, Yun H, Fu CX, Ge JB, Jin H, Qian JY, Zhang WG (2016) Myocardial extracellular volume fraction measurement in chronic total coronary occlusion: association with myocardial injury, angiographic collateral flow, and functional recovery. J Magn Reson Imaging 44:972–982. doi:10.1002/jmri.25235 PubMedCrossRef

63.

Dall'Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, Cuculi F, Kharbanda RK, Banninq AP, Choudhury RP, Karamitsos TD, Neubauer S (2012) Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson 14:15–28. doi:10.1186/1532-429X-14-15 PubMedPubMedCentralCrossRef

64.

Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE (2012) Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J Am Coll Cardiol Img 5:596–603. doi:10.1016/j.jcmg.2012.01.016 CrossRef

65.

Kellman P, Bandettini WP, Mancini C, Hammer-Hansen S, Hansen MS, Arai AE (2015) Characterization of myocardial T1-mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques. J Cardiovasc Magn Reson 17:33PubMedPubMedCentralCrossRef

66.

Liu A, Wijesurendra RS, Ariga R, Mahmod M, Levelt E, Greiser A, Petrou M, Krasopoulos G, Forfar JC, Kharbanda RK, Channon KM, Neubauer S, Piechnik SK, Ferreira VM (2017) Splenic T1-mapping: a novel quantitative method for assessing adenosine stress adequacy for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 19:1–11. doi:10.1186/s12968-016-0318-2 PubMedPubMedCentralCrossRef

67.

Manisty C, Ripley DP, Herrey AS, Captur G, Wong TC, Petersen SE, Plein S, Peebles C, Schelbert EB, Greenwood JP, Moon JC (2015) Splenic switch-off: a tool to assess stress adequacy in adenosine perfusion cardiac MR imaging. Radiology 276(3):732–740PubMedCrossRef

68.

Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120:1203–1212. doi:10.1161/CIRCULATIONAHA.108.843334 PubMedCrossRef

69.

Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img 3:155–164. doi:10.1016/j.jcmg.2009.09.023 CrossRef

70.

Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Img 6:488–497. doi:10.1016/j.jcmg.2012.11.013 CrossRef

71.

Ruberg FL (2013) T1 mapping in cardiac amyloidosis: can we get there from here? J Am Coll Cardiol Img 6:498–500. doi:10.1016/j.jcmg.2013.01.007 CrossRef

72.

Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ (2014) CMR-based differentiation of AL and ATTR cardiac amyloidosis. J Am Coll Cardiol Img 7:133–142. doi:10.1016/j.jcmg.2013.08.015 CrossRef

73.

Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R (2005) Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112:535–543. doi:10.1161/CIRCULATIONAHA.104.504415 PubMedPubMedCentralCrossRef

74.

de Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J, Pasquet A, Vancreaynest D, Pouleur AC, Vanoverschelde JLJ, Gerber BL (2015) Histological validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from modified look-locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson 17:48–59. doi:10.1186/s12968-015-0150-0 PubMedPubMedCentralCrossRef

75.

Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281–308. doi:10.1161/CIR.0b013e31829b2be6 PubMedCrossRef

76.

Torlasco C, Cassinerio E, Pedrotti P, Faini A, Capecchi M, Abdel-Gadir A, Parati G. Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment. In: BMJ publishing group Proceedings 24th great wall international congress of cardiology/Asia pacific heart congress/international congress of cardiovascular prevention and rehabilitation. Beijing, pp A6–A6. doi:10.1136/heartjnl-2017-311399.6

77.

Feng Y, He T, Carpenter JP, Jabbour A, Alam M, Gatehouse PD, Greiser A, Messorgli D, Firmin DN, Pennell DJ (2013) In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major. J Magn Reson Imaging 38:588–593. doi:10.1002/jmri.24010

78.

Alam MH, Auger D, Smith GC, He T, Vassiliou V, Baksi AJ, Wage R, Drivas P, Feng Y, Firmin DN, Pannell DJ (2015) T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis. J Cardiovasc Magn Reson 17:102–113. doi:10.1186/s12968-015-0207-0 PubMedPubMedCentralCrossRef

79.

Camargo GC, Rothstein T, Junqueira FP, Fernandes E, Greiser A, Strecker R, Pessoa V, Lima RS, Gottlieb I (2016) Comparison of myocardial T1 and T2 values in 3 T with T2* in 1.5 T in patients with iron overload and controls. Int J Hematol 103:530–536. doi:10.1007/s12185-016-1950-1 PubMedCrossRef

80.

Kirk P, Smith GC, Roughton M, He T, Pennell DJ (2010) Myocardial T2* is not affected by ageing, myocardial fibrosis, or impaired left ventricular function. J Magn Reson Imaging 32:1095–1098. doi:10.1002/jmri.22348 PubMedCrossRef

81.

Carpenter J-P, Prasad SK, Pennell DJ (2009) Myocardial fibrosis in thalassaemia: recalling the past or telling the future? Heart 95:1646–1647PubMedCrossRef

82.

Lehrke S, Lossnitzer D, Schöb M, Steen M, Merten C, Kemmling H, Pribe R, Ehlermann P, Zuqck C, Korosoglou G, Giannitsis E, Katus HA (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97:727–732. doi:10.1136/hrt.2010.205542 PubMedCrossRef

83.

Kellman P, Hansen MS (2014) T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson 16:2–22. doi:10.1186/1532-429X-16-2 PubMedPubMedCentralCrossRef

84.

Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R, Mahmod M, Cochlin L, Karamitsos TD, Robson MD, Watkins H, Neubauer S (2012) Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 5:726–733. doi:10.1161/CIRCIMAGING.112.976738 PubMedCrossRef

85.

Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, Pastor A, Carr-White G, Razavi R, Schaeffter T, Nagel E (2013) Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. J Am Coll Cardiol Img 6:475–484. doi:10.1016/j.jcmg.2012.08.019 CrossRef

86.

Barison A, Del Torto A, Chiappino S, Aquaro GD, Todiere G, Verqaro G, Passino C, Lombardi M, Emdin M, Masci PG (2015) Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 16:681–687. doi:10.2459/JCM.0000000000000275 CrossRef

87.

Hong YJ, Park CH, Kim YJ, Hur J, Lee HJ, Hong SR, Suh YJ, Greiser A, Paek MY, Choi BW, Kim TH (2015) Extracellular volume fraction in dilated cardiomyopathy patients without obvious late gadolinium enhancement: comparison with healthy control subjects. Int J Cardiovasc Imaging 31(Suppl 1):115–122. doi:10.1007/s10554-015-0595-0 PubMedCrossRef

88.

Sanz J (2016) T1 maps in nonischemic DCM: do they show us the way? J Am Coll Cardiol Img 9:51–53. doi:10.1016/j.jcmg.2015.11.007 CrossRef

89.

Nishii T, Kono AK, Shigeru M, Takamine S, Fujiwara S, Kyotani K, Aoyama N, Sugimura K (2014) Cardiovascular magnetic resonance T2 mapping can detect myocardial edema in idiopathic dilated cardiomyopathy. Int J Cardiovasc Imaging 30(Suppl 1):65–72PubMedCrossRef

90.

Kamal MU, Riaz IB, Janardhanan R (2016) Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: current state of the art. Cardiol J 23:250–263. doi:10.5603/CJ.a2016.0019 PubMedCrossRef

91.

Lu M, Zhao S, Yin G, Jiang S, Zhao T, Chen X, Tian L, Zhang Y, Wei Y, Liu Q, He Z, Xue H, An J, Shah S (2013) T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: a preliminary study. Eur J Radiol 82:e225–e231. doi:10.1016/j.ejrad.2012.12.014 PubMedCrossRef

92.

Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO (2015) T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 8:e003285. doi:10.1161/CIRCIMAGING.115.003285 PubMedCrossRef

93.

Lima JAC (2013) The promise of myocardial fibrosis assessment by T1 mapping. J Am Coll Cardiol Img 6:485–487. doi:10.1016/j.jcmg.2012.11.014 CrossRef

94.

Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, Ferguson C, Page SP, Greenwood JP, Plein S (2016) Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete’s heart. JAC 67:2189–2190. doi:10.1016/j.jacc.2016.02.054

95.

Badiani S, van Zalen J, Treibel TA, Bhattacharyya S, Moon JC, Lloyd G (2016) Aortic stenosis, a left ventricular disease: insights from advanced imaging. Curr Cardiol Rep 18:80. doi:10.1007/s11886-016-0753-6 PubMedPubMedCentralCrossRef

96.

Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS, Hausenlov DJ, Ariti C, Yap J, Kolvekar S, Taylor AM, Moon JC (2012) Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 13:819–826. doi:10.1093/ehjci/jes102 PubMedCrossRef

97.

Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, Francis JM, Karamitsos TD, Prenderqast BD, Robson MD, Neubauer S, Moon JC, Myerson SG (2013) Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 99:932–937. doi:10.1136/heartjnl-2012-303052 PubMedPubMedCentralCrossRef

98.

Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, Beer M, Gattenlohner S, Voelker W, Ertl G, Strotmann JM (2009) Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120:577–584PubMedCrossRef

99.

Chin CWL, Messika-Zeitoun D, Shah ASV, Lefevre G, Bailleul S, Yeung ENW, Koo M, Mirsadraee S, Mathieu T, Semple SI, Mills NL, Vahanian A, Newby DE, Dweck MR (2016) A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. Eur Heart J 37:713–723. doi:10.1093/eurheartj/ehv525 PubMedCrossRef

100.

Nadjiri J, Nieberler H, Hendrich E, Will A, Pellegrini C, Husser O, Hengstenberg C, Greiser A, Martinoff S, Hadamitzky M (2016) Prognostic value of T1-mapping in TAVR patients: extra-cellular volume as a possible predictor for peri- and post-TAVR adverse events. Int J Cardiovasc Imaging 32:1625–1633. doi:10.1007/s10554-016-0948-3 PubMedCrossRef

101.

Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC (2016) Myocardial fibrosis and cardiac decompensation in aortic stenosis. J Am Coll Cardiol Img. doi:10.1016/j.jcmg.2016.10.007

102.

Edwards NC, Moody WE, Yuan M, Weale P, Neal D, Townend JN, Steeds RP (2014) Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. Circ Cardiovasc Imaging 7:946–953. doi:10.1161/CIRCIMAGING.114.002397 PubMedCrossRef

103.

Captur G, Gatehouse P, Keenan KE, Heslinga FG, Bruehl R, Prothmann M, Graves MJ, Eames RJ, Torlasco C, Benedetti G, Donovan J, Ittermann B, Boubertakh R, Bathgate A, Royet C, Pang W, Nezafat R, Salerno M, Kellman P, Moon JC (2016) A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance—the T1 mapping and ECV standardization in CMR (T1MES) program. J Cardiovasc Magn Reson 18(1):58–78PubMedPubMedCentralCrossRef

104.

Vassiliou V, Heng E, Donovan J, Greiser A, Babu-Narayan SV, Gatzoulis MA, Firmin D, Pennell DJ, Gatehouse P, Prasad SK (2015) Longitudinal stability of gel T1 MRI phantoms for quality assurance of T1 mapping. J Cardiovasc Magn Reson 17(Suppl 1):W28–W31PubMedCentralCrossRef

105.

Captur G, Manisty C, Moon JC (2016) Cardiac MRI evaluation of myocardial disease. Heart 102:1429–1435PubMedCrossRef

106.

O’Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh D-M, Lacombe D, Lambin P, Lassau N, Leach MO, Lee T-Y, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJM, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC (2016) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol advance on 14(3):169–186CrossRef

107.

Roujol S, Weingärtner S, Foppa M, Chow K, Kawaji K, Ngo LH, Kellman P, Manning WJ, Thompson RB, Nezafat R (2014) Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 272:683–689PubMedPubMedCentralCrossRef

108.

Weingärtner S, Meßner NM, Zöllner FG, Akçakaya M, Schad LR (2016) Black-blood native T₁ mapping: blood signal suppression for reduced partial voluming in the myocardium. Magn Reson Med. doi:10.1002/mrm.26378

109.

Ferreira VM, Wijesurendra RS, Liu A, Greiser A, Casadei B, Robson MD, Neubauer S, Piechnik SK (2015) Systolic ShMOLLI myocardial T1-mapping for improved robustness to partial-volume effects and applications in tachyarrhythmias. J Cardiovasc Magn Reson 17:77. doi:10.1186/s12968-015-0182-5 PubMedPubMedCentralCrossRef

110.

Sussman MS, Yang IY, Fok K-H, Wintersperger BJ (2016) Inversion group (IG) fitting: a new T1 mapping method for modified look-locker inversion recovery (MOLLI) that allows arbitrary inversion groupings and rest periods (including no rest period). Magn Reson Med 75:2332–2340PubMedCrossRef

111.

Chow K, Yang Y, Shaw P, Kramer CM, Salerno M (2016) Robust free-breathing SASHA T1 mapping with high-contrast image registration. J Cardiovasc Magn Reson 18(1):47. doi:10.1186/s12968-016-0267-9 PubMedPubMedCentralCrossRef

112.

Weingärtner S, Akçakaya M, Basha T, Kissinger KV, Goddu B, Berg S, Manning WJ, Nezafat R (2014) Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med 71:1024–1034. doi:10.1002/mrm.24761 PubMedCrossRef

113.

Zhao L, Li S, Ma X, Greiser A, Zhang T, An J, Bai R, Dong J, Fan Z (2016) Systolic MOLLI T1 mapping with heart-rate-dependent pulse sequence sampling scheme is feasible in patients with atrial fibrillation. J Cardiovasc Magn Reson 18:13. doi:10.1186/s12968-016-0232-7 PubMedPubMedCentralCrossRef

114.

Roujol S, Foppa M, Kawaji K, Kissinger KV, Goddu B, Manning WJ, Nezafat R (2014) Improved motion correction for T1 mapping. J Cardiovasc Magn Reson 16:P45. doi:10.1186/1532-429X-16-S1-P45 PubMedCentralCrossRef

115.

Blume U, Lockie T, Stehning C, Sinclair S, Uribe S, Razavi R, Schaeffter T (2009) Interleaved T1 and T2 relaxation time mapping for cardiac applications. J Magn Reson Imaging 29:480–487PubMedCrossRef

116.

Hamilton JI, Jiang Y, Chen Y, Ma D, Lo W-C, Griswold M, Seiberlich N (2017) MR fingerprinting for rapid quantification of myocardial T1, T2, and proton spin density. Magn Reson Med 77:1446–1458PubMedCrossRef

117.

Ingravallo F, Dietrich CF, Gilja OH, Piscaglia F (2014) Guidelines, clinical practice recommendations, position papers and consensus statements: definition, preparation, role and application. Ultraschall Med 35:395–399PubMedCrossRef

Title: T1 mapping in cardiac MRI
Authors: Dina Radenkovic
Sebastian Weingärtner
Lewis Ricketts
James C. Moon
Gabriella Captur
Publication date: 01-07-2017
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 4/2017
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-017-9627-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

T₁ mapping in cardiac MRI

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Introduction to the Special Issue: Myocardial Imaging in Heart Failure

The role of myocardial viability in contemporary cardiac practice

Strain imaging using cardiac magnetic resonance

Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: current state and future directions

PET imaging in heart failure: the role of new tracers

T2 mapping and T2* imaging in heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page